NTQ6179 not checked
Nanjing Chia-tai Tianqing Pharmaceutical
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NTQ6179 tablets, an oral non-peptide small-molecule somatostatin receptor subtype 2 (SSTR2) agonist, administered orally as a single dose with approximately 240 milliliters (mL) of water under fasting conditions (at least 10 hours of overnight fasting prior to dosing).”In the company’s words, NCT07909837 on ClinicalTrials.gov
- Tested for
- Acromegaly
- Main trialPhase 1
- “This is a phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of single oral doses of NTQ6179 tablets in healthy participants. A total of 56 healthy participants will be enrolled in 7 sequential dose cohorts, with an allocation ratio of NTQ6179 to placebo of 6:2 in each cohort.”In the company’s words, NCT07909837 on ClinicalTrials.gov
Other drugs for Acromegaly
- MAR002Marea Therapeutics · Phase 2
Coming up1
- Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Apr 2027 | A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026